Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Bazlitoran (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIONEER
- Sponsors Aceragen; Idera Pharmaceuticals
- 08 Aug 2020 Results published in the Journal of the American Academy of Dermatology
- 24 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.